EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Cost‐effectiveness analysis of abrocitinib compared with standard of care in adult moderate‐to‐severe atopic dermatitis in Japan

Akio Tanaka iD, Akira Yuasa iD, Kazumasa Kamei, Mitsuhiro Nagano, Toshiaki Murofushi, Annika Bjerke, Kouki Nakamura, Shunya Ikeda

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17234 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Akio Tanaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Dermatitis, Atopic, Quality-Adjusted Life Years, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Japan Inc., Pfizer Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a significant clinical, economic, and human burden. The JAK1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials demonstrated that as a treatment for moderate‐to‐severe AD in adults with previous exposure to immunotherapy, abrocitinib showed superior efficacy and safety compared with standard of care (SoC), consisting of topical corticosteroids. This study assessed the cost‐effectiveness of abrocitinib with SoC versus SoC alone for this patient population in Japan from a societal perspective. A hybrid decision tree and Markov model were used to capture the initial treatment and long‐term maintenance phases. Clinical inputs at 16 weeks were obtained through a Bayesian network meta‐analysis of four pivotal trials from the JADE program. Clinical inputs at 52 weeks were derived from the JADE EXTEND trial. Response‐specific utility inputs were obtained from published literature. Resource use, costs, and productivity inputs were gathered from Japanese claims analysis, literature, public documents, and expert opinion. Costs and quality‐adjusted life years (QALYs) were discounted at 2.0% per year and incremental cost‐effectiveness ratios (ICERs) were calculated. Sensitivity and scenario analyses were performed to validate the base case results and explore a payer perspective. Over a lifetime horizon and with the base‐case societal perspective, abrocitinib produced a mean gain of 0.75 QALYs, incremental costs of JPY (¥) 2 270 386 (USD [$] 17 265.6), and a resulting ICER of ¥3 034 514 ($23 076.5) per QALY compared with SoC. From a payer perspective, the incremental costs increased to ¥4 476 777 ($34 044.4), with an ICER of ¥5 983 495 ($45 502.6) per QALY. The results were most sensitive to treatment‐specific, response‐based utility weights, drug costs, and productivity‐related inputs. From a Japanese societal perspective, abrocitinib demonstrated superior QALYs and with a willingness‐to‐pay threshold of ¥5 000 000 ($38 023.4) per QALY, can be considered cost‐effective compared with SoC as a treatment for moderate‐to‐severe AD in adult patients with previous immunosuppressant exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisDermatitis, AtopicQuality-Adjusted Life YearsPyrimidinesStandard of CareHumansJapanAdultSeverity of Illness IndexSulfonamidesMaleTreatment OutcomeFemaleMarkov ChainsAdrenal Cortex HormonesDrug CostsCost-Effectiveness Analysis

Stichwörter der Autor:innen

Japanabrocitinibatopic dermatitiscost‐effectiveness analysisproductivity loss

Substanzen

abrocitinibPyrimidinesSulfonamidesAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan.
  • HEOR, Value & Access, INTAGE Healthcare Inc., Tokyo, Japan.
  • Modeling and Analytics, Lumanity, Bethesda, Maryland, USA.
  • Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
  • Department of Public Health, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.

ORCID-Profile: Akio Tanaka, Akira Yuasa

Förderung

  • Pfizer Japan Inc.
  • Pfizer Japan

Zitieren

APA

Tanaka, A., Yuasa, A., Kamei, K., Nagano, M., Murofushi, T., Bjerke, A., Nakamura, K., & Ikeda, S. (2024). Cost‐effectiveness analysis of abrocitinib compared with standard of care in adult moderate‐to‐severe atopic dermatitis in Japan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17234

Vancouver

Tanaka A, Yuasa A, Kamei K, Nagano M, Murofushi T, Bjerke A, et al. Cost‐effectiveness analysis of abrocitinib compared with standard of care in adult moderate‐to‐severe atopic dermatitis in Japan. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17234

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Akio and Yuasa, Akira and Kamei, Kazumasa and Nagano, Mitsuhiro and Murofushi, Toshiaki and Bjerke, Annika and Nakamura, Kouki and Ikeda, Shunya},
  title = {Cost‐effectiveness analysis of abrocitinib compared with standard of care in adult moderate‐to‐severe atopic dermatitis in Japan},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17234}
}
Kostenlos starten →